Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

ABSTRACT:

Background

Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear.

Methods

In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously received at least one platinum-based chemotherapy regimen to receive either lenvatinib (20 mg, administered orally once daily) plus pembrolizumab (200 mg, administered intravenously every 3 weeks) or chemotherapy of the treating physician's choice (doxorubicin at 60 mg per square meter of body-surface area, administered intravenously every 3 weeks, or paclitaxel at 80 mg per square meter, administered intravenously weekly [with a cycle of 3 weeks on and 1 week off]). The two primary end points were progression-free survival as

SUBMITTER: Makker V 

PROVIDER: S-EPMC11651366 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature